Clinical Trial

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

Study acronym: RENEW-IBS-D
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with placebo. The study will last approximately 35 weeks.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07545759
Lead Sponsor Eli Lilly and Company
Conditions Irritable Bowel Syndrome, Diarrhea
Enrollment 531 participants
Start Date 2026-05-06
Primary Completion 2027-09 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-06